Literature DB >> 2859902

Serum amyloid A protein during the treatment of rheumatoid arthritis with second-line drugs.

K A Grindulis, D L Scott, M W Robinson, P A Bacon, B McConkey.   

Abstract

Serum amyloid A protein (SAA), serum C-reactive protein (CRP) and the ESR were measured in 19 patients with rheumatoid arthritis before treatment and during therapy with gold, penicillamine or sulphasalazine for a mean period of 14.8 months (range 6-23 months). All three measurements decreased significantly; however, only 7% of SAA values fell to within the normal range (18-44 mg/l), compared to 38% measurements of serum CRP (less than 10 mg/l) and 32% of the ESR (less than 25 mm/h). In 8 (42%) of the 19 patients, SAA remained high (greater than 400 mg/l) for 3 months or more whilst serum CRP was depressed below 20 mg/l; this discrepancy was not related to particular drugs. We conclude that during treatment of rheumatoid arthritis with gold, penicillamine or sulphasalazine, SAA concentrations can be high when serum CRP and ESR are suppressed. SAA may be a more sensitive index of disease activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859902     DOI: 10.1093/rheumatology/24.2.158

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  3 in total

Review 1.  Amyloidosis in the rheumatic diseases.

Authors:  V Dhillon; P Woo; D Isenberg
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

2.  Comparison of serum amyloid A and C-reactive protein as diagnostic markers of systemic inflammation in dogs.

Authors:  Michelle B Christensen; Rebecca Langhorn; Amelia Goddard; Eva B Andreasen; Elena Moldal; Asta Tvarijonaviciute; Jolle Kirpensteijn; Sabrina Jakobsen; Frida Persson; Mads Kjelgaard-Hansen
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

3.  The clinical value of measuring immunoglobulins when assessing penicillamine therapy in rheumatoid arthritis.

Authors:  A Williams; D L Scott; A Greenwood; E C Huskisson
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.